This inventor holds 53 USPTO granted patents, primarily in Dihydropyridine Chemistry (CPC class 5143). Top assignees: Bayer Aktiengesellschaft, Other. Active years: 1979-2006.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Inventors with similar research interests:
Location History:
- Haan, DE (1979 - 2000)
- Hann, DE (2006)
Company Filing History:
52 out of 12,268 
1 out of 834,513 Years Active: 1979-2006
Areas of Expertise:
Title: Unveiling the Innovations of Inventor Jurgen Stoltefuss from Haan, DE
Introduction:
Jurgen Stoltefuss, a prolific inventor hailing from Haan, DE, has left a remarkable imprint in the realm of patents with an impressive portfolio of 53 patents. His groundbreaking work has significantly contributed to the field of medicinal chemistry and the development of innovative pharmaceutical solutions.
Latest Patents:
Among his latest patents include:
1. Medicaments against viral diseases - Novel dihydropyrimidines: These compounds, in combination with other antiviral agents, have shown promise in combating HBV infections, offering new avenues in the treatment of viral diseases.
2. Cycloalkano-pyridines for hyperlipoproteinaemia and arteriosclerosis: Stoltefuss's research has led to the synthesis of cycloalkano-pyridines, which exhibit potential as active compounds in medicaments targeting hyperlipoproteinaemia and arteriosclerosis.
Career Highlights:
Jurgen Stoltefuss has notably worked with esteemed companies such as Bayer Aktiengesellschaft, where his expertise and innovative spirit have flourished. His tenure at Bayer Aktiengesellschaft has been marked by pioneering research and the development of groundbreaking pharmaceutical solutions.
Collaborations:
Throughout his career, Stoltefuss has collaborated closely with esteemed professionals in the field, including Rainer Gross and Martin Bechem. Their collaborative efforts have resulted in the successful development and patenting of novel compounds, further solidifying Stoltefuss's reputation as a visionary inventor.
Conclusion:
In conclusion, Jurgen Stoltefuss's relentless pursuit of innovation and his invaluable contributions to medicinal chemistry have established him as a trailblazer in the field of pharmaceutical research. His prolific portfolio of patents stands as a testament to his visionary thinking and unwavering dedication to advancing healthcare solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile